A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
ICAN
1 other identifier
observational
591
1 country
13
Brief Summary
This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2010
Typical duration for all trials
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 14, 2010
CompletedFirst Posted
Study publicly available on registry
April 20, 2010
CompletedStudy Start
First participant enrolled
August 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2014
CompletedMarch 18, 2014
March 1, 2014
3.4 years
April 14, 2010
March 17, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
type and prevalence of EGFR mutation
up to 3 months
Secondary Outcomes (2)
Operation type and adjuvant treatment type
up to 3 months
Disease Free Survival rate
up to 3 months
Study Arms (1)
1
Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.
Eligibility Criteria
Patients from Thoracic surgery department
You may qualify if:
- Histological diagnosed as adenocarcinoma type of non-small cell lung cancer
- Have completed lung cancer operation
- The tumour EGFR gene mutation status test was performed as regular medical practice
You may not qualify if:
- Patients who disagree to participate this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (13)
Research Site
Beijing, Beijing Municipality, China
Research Site
Chongqing, Chongqing Municipality, China
Research Site
Guangzhou, Guangdong, China
Research Site
Wuhan, Hubei, China
Research Site
Nanjing, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
Research Site
Changchun, Jilin, China
Research Site
Shenyang, Liaoning, China
Research Site
Qingdao, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Chengdu, Sichuan, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Hangzhou, Zhejiang, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Karen Atkin
Astrazeneca China R&D
- PRINCIPAL INVESTIGATOR
Wu Yilong
Guangdong Provincial People's Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 14, 2010
First Posted
April 20, 2010
Study Start
August 1, 2010
Primary Completion
January 1, 2014
Study Completion
January 1, 2014
Last Updated
March 18, 2014
Record last verified: 2014-03